This content is from: Patents

Brands fear effects of ANDA venue win – but should they?

BMS, Sanofi and others say a Federal Circuit ruling, if affirmed in a rehearing, could reshape Hatch-Waxman litigation. Others think it only affects Mylan

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial